Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Surgeon General
  • Cigna’s ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

TRENDING TOPICS:

  • Surgeon General
  • Cigna's ACA Exit
  • Visa Program
  • Medicaid Work Requirements
  • Gavin Newsom

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jul 1 2020

Full Issue

FDA Sets Bar For COVID-19 Vaccine Approval: Must Prevent Or Decrease Disease Severity For At Least Half

The FDA released guidance Tuesday on the criteria it will use to approve any coronavirus vaccine. Any candidates must prevent or decrease disease severity in at least 50% of the people inoculated. Temporary authorizations may be considered on a “case-by-case basis,” the agency said.

The Washington Post: FDA Will Require Covid-19 Vaccine To Be At Least 50 Percent More Effective Than Placebo, Agency Says 

The Food and Drug Administration said Tuesday that to win regulatory approval, any covid-19 vaccine will have to prevent disease, or decrease its severity, in at least 50 percent of the people who receive it. The agency also said it would require drug companies to monitor the vaccine’s performance after approval for any emerging safety problems. (McGinley, 6/30)

Reuters: U.S. FDA Comes Out With Guidance For COVID-19 Vaccine Approval 

“While the FDA is committed to expediting this work, we will not cut corners in our decisions,” the FDA said on Tuesday. ... “The guidelines are pretty standard, they look pretty much like influenza vaccine guidelines,” Gregory Poland, director of Mayo Vaccine Research Group said. “I don’t think that’s a high bar. I think that’s a low to maybe an appropriate bar for a first-generation COVID-19 vaccine.” (Maddipatla and Nadeem, 6/30)

The Hill: Trump Officials Seek To Reassure Public About Safety Of A Potential Coronavirus Vaccine 

Top Trump administration health officials are seeking to reassure the public that any potential coronavirus vaccine will only be approved if it is safe and that the fast-track process won't be influenced by political pressure. Democratic lawmakers and public health experts have expressed concern that President Trump's focus on developing a vaccine will pressure the Food and Drug Administration into approving one before it's safe. (Weixel, 6/30)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF